Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05666310 · ClinicalTrials.gov registry record · Phase 4
Muscle Impact of Treating Osteoporosis
A Phase 4 study of Osteoporosis and Sarcopenia, sponsored by Nami Safai Haeri.
- Active
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05666310 is a Phase 4 study of Osteoporosis and Sarcopenia that is active but no longer recruiting, run by Nami Safai Haeri. The registered enrollment target is 20 participants, below the 1,546-participant average among 84 other Osteoporosis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05666310, a Phase 4 study of Osteoporosis and Sarcopenia, is active but no longer recruiting, sponsored by Nami Safai Haeri.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Osteosarcopenia is a geriatric musculoskeletal syndrome characterized by co-existence of osteoporosis and sarcopenia (low skeletal muscle mass, strength, and/or functional capacity). There is strong evidence of overlap between the pathophysiology of osteoporosis and sarcopenia (muscle-bone crosstalk). This research plan will further explore the relationship between bone and muscle, and provide new information about effect of osteoporosis medications on muscle health in older adults who are under treatment for osteoporosis.
Conditions Studied
Interventions
- DRUG Denosumab
- DRUG Zoledronic Acid
- OTHER Denosumab Placebo
- OTHER Zoledronic Acid Placebo
Study Locations (1)
Pennsylvania
- University of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-02-14 |
| Est. Completion | 2026-09-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05666310
The ClinicalTrials.gov registry entry for NCT05666310 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,546-participant average among 84 other Osteoporosis trials with a reported enrollment target (99% lower). The listed sponsor is Nami Safai Haeri, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Osteoporosis appearing as the primary indexed condition, and to 4 interventions - of which Denosumab is the first listed.
NCT05666310 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05666310 about?
NCT05666310 is a clinical study titled "Muscle Impact of Treating Osteoporosis". Osteosarcopenia is a geriatric musculoskeletal syndrome characterized by co-existence of osteoporosis and sarcopenia (low skeletal muscle mass, strength, and/or functional capacity). There is strong evidence of overlap between the pathophysiology of osteoporosis and sarcopenia (muscle-bone crosstalk...
What is the current status of trial NCT05666310?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2023-02-14. Estimated completion is 2026-09-05.
What conditions does trial NCT05666310 study?
This clinical trial studies the following conditions: Osteoporosis, Sarcopenia.
What interventions are being tested in trial NCT05666310?
The interventions under investigation include: Denosumab (DRUG), Zoledronic Acid (DRUG), Denosumab Placebo (OTHER), Zoledronic Acid Placebo (OTHER).
Who is sponsoring clinical trial NCT05666310?
This trial is sponsored by Nami Safai Haeri, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05666310 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preserving Geriatric Muscle With an Osteoporosis Medication
RECRUITING · Phase 4
-
Combined Anabolic Therapy
RECRUITING · Phase 4
-
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI
ACTIVE NOT RECRUITING · Phase 4
-
Denosumab (DMAB) Discontinuation and Switching in Glucocorticoid-Induced Osteoporosis (GIOP): a Pilot Study
ACTIVE NOT RECRUITING · Phase 4
-
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
ACTIVE NOT RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.